Abstract:ObjectiveTo investigate the value of combined measurement of alpha-fetoprotein (AFP) and AFP-L3% in the diagnosis of hepatocellular carcinoma (HCC). MethodsA retrospective analysis was performed for serological parameters and clinical data of 1208 patients with chronic hepatitis, 1967 patients with liver cirrhosis, and 1569 patients with primary HCC who attended The Fifth Medical Center of Chinese PLA General Hospital from January 2010 to December 2017. The distribution of serum AFP and AFP-L3% was analyzed, and AFP alone, AFP-L3% alone, and AFP combined with AFP-L3% were compared in terms of sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). The correlation of AFP with AFP-L3 level and AFP-L3% was also analyzed. A one-way analysis of variance or the Kruskal-Wallis H test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. The Spearman rank correlation test was used for correlation analysis of continuous data, the Delong test was used for comparison of AUC, and logistic regression was used to establish the model of AFP combined with AFP-L3% for the diagnosis of HCC. ResultsThe HCC group had significantly higher serum levels of AFP and AFP-L3 than the liver cirrhosis group and the chronic hepatitis group (H=1107.3 and 1076.9, both P＜0.01). The HCC group had a significantly higher positive rate of AFP-L3% than the liver cirrhosis group and the chronic hepatitis group (30.9% vs 3.0%/2.8%, P＜0.01). The HCC group had a significantly higher level of AFP-L3 than the liver cirrhosis group and the chronic hepatitis group （3.3(0-13.4)% vs 0/0, H=1034.1, P＜001）. The correlation analysis showed that serum AFP was significantly correlated with AFP-L3 level (r=0.91, P＜0.01), and there was no correlation between AFP-L3% and AFP (r=0.04, P＞0.05). With specificity remaining the same, AFP combined with AFP-L3% had a significantly higher sensitivity in the diagnosis of HCC than AFP alone (26.6% vs 18.4%, P＜0.01) or AFP-L3% alone (36.6% vs 30.9%, P＜0.01). The subgroup analysis showed that for the samples with AFP ≥10 μg/L, AFP combined with AFP-L3% had a significantly higher AUC in the diagnosis of HCC than AFP alone (0.745 vs 0.701, P＜0.01); for the tumor with a diameter of ＞2 cm or hepatitis B-related liver cancer, AFP combined with AFP-L3% had a significantly higher sensitivity than AFP alone (27.6% vs 180%/27.7% vs 19.1%, both P＜0.01) or AFP-L3% alone (37.0% vs 30.3%/36.9% vs 31.8%, both P＜0.01). For the group with a tumor diameter of ≤2 cm and the group without hepatitis B-related liver cancer, there was no significant difference in sensitivity between AFP combined with AFP-L3% and AFP or AFP-L3% alone in the diagnosis of HCC (all P＞0.05). ConclusionAFP combined with AFP-L3% can significantly improve the sensitivity of HCC diagnosis and has a good clinical value in the diagnosis of hepatitis B-related liver cancer and liver cancer with a tumor diameter of ＞2 cm.

Diagnostic value of Golgi protein 73 alone and in combination with alpha fetoprotein in hepatocellular carcinoma

Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta- analysis

[Detection and Evaluation of Serum GP73, a Resident Golgi Glycoprotein, As a Marker in Diagnosis of Hepatocellular Carcinoma].

Combined determination of serum DCP, GPC3 and HSP70 in diagnosis of AFP-negative primary liver carcinoma

Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma

Advances on Golgi Glycoprotein 73 and Its Association with Diseases

Diagnostic Value of Glypican-3, Arginase-1 and Hepatocyte Paraffin Antigen -1 in Differentiating Hepatocellular Carcinoma from Intrahepatic Cholangiocarcinoma

Serum Golgi protein 73 as a tumor marker in diagnosis of primary hepatic cancer

The Value of Serum Glypican-3 Level in Aided Diagnosis of Patients with Primary Hepatocellular Carcinoma

Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer

Whether the Golgi protein 73 could be a diagnostic serological marker in hepatocellular carcinoma: a meta analysis

The Diagnostic Potential of Golgi Protein 73 for Cirrhosis in Patients with Chronic Hepatitis C

Golgi Protein 73(GP73), a Useful Serum Marker in Liver Diseases

Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.

High Expression of GP73 in Primary Hepatocellular Carcinoma and Its Function in the Assessment of Transcatheter Arterial Chemoembolization.

Expression of GP73 in Liver Cirrhosis and Its Assistant Value in Grading of Liver Cirrhosis

A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma

Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma.

Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries

Value of combined measurement of alpha-fetoprotein and alpha-fetoprotein L3％in the diagnosis of hepatocellular carcinoma

Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma